Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial) Authors
First Online: 31 October 2008 DOI:
Cite this article as: Litvinenko, I.V., Odinak, M.M., Mogil’naya, V.I. et al. Neurosci Behav Physi (2008) 38: 937. doi:10.1007/s11055-008-9077-3 Abstract
An open controlled trial of the use of galantamine at a maximum dose of 16 mg/day included 41 patients with Parkinson's disease with dementia randomized to a galantamine treatment group (21 patients) and a control group (20 patients). Cognitive, neuropsychiatric, and motor symptoms were assessed clinically before the trial and at 4, 12, and 24 weeks, using the Mini Mental State Examination (MMSE), the cognitive Alzheimer's Disease Assessment Scale (ADAS-cog), the clock drawing test, the Frontal Assessment Battery (FAB), and the Neuropsychiatric Inventory (NPI) with assessment of distress in relatives. Patients treated with galantamine had better scores on the MMSE (
p < 0.05),ADAS-cog ( p < 0.05), the clock drawing test ( p < 0.05), and the FAB ( p < 0.01) at the end of the study period as compared with the control group. Changes in total point scores on the NPI-12 at the ends of weeks 12 and 24, as compared with the beginning of the trial, were in favor of the group treated with galantamine, with significant changes in the hallucinations ( p = 0.0002), anxiety ( p = 0.04), sleep disturbance ( p = 0.04), and apathy ( p = 0.006) sections. Galantamine treatment was accompanied by decreases in the level of distress in patients' relatives ( p = 0.007) and improvements in daily activity ( p = 0.003). Improvements in gait and decreases in freezing and falls were seen in the galantamine treatment group. However, two patients of this group showed minor increases in tremor. Side effects (drooling, postural hypotension, nausea, dysuria) occurred in seven patients (30%). Key Words Parkinson's disease dementia galantamine
Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 107, No. 12, pp. 25–33, December, 2007.
Download to read the full article text References
Zh. M. Glozman and O. S. Levin, “Mental disorders in extrapyramidal diseases,” in:
Extrapyramidal Diseases: Handbook of Diagnosis and Treatment [in Russian], V. N. Shtok, I. A. Ivanova-Smolenskaya, and O. S. Levin (eds.), MEDpress-Inform, Moscow (2002), pp. 74–86.
V. L. Golubev, Ya. I. Levin, and A. M. Vein,
Parkinson's disease and Parkinson's Syndrome [in Russian], MEDpress, Moscow (1999).
O. S. Levin and N. A. Amosova,
Psychotic Disorders in Parkinson's disease. Scientific-Practical Conference on Parkinson's Disease [in Russian], Moscow (1999), pp. 30–32.
O. S. Levin, “Efficacy of Reminyl in dementia with Lewy bodies,”
Zh. Nevropatol. Psikhiat., 105, No. 10, 15–21 (2005).
D. Aarsland, J. P. Larsen, J. L. Cumming, et al., “Prevalence and clinical correlates of psychotic symptoms in Parkinson's disease,”
, No. 3, 595–601 (1999).
D. Aarsland, K. Andersen, J. P. Larsen, et al., “Risk of dementia in Parkinson's Disease: A community-based prospective study,”
, No. 6, 730–736 (2001).
D. Aarsland, M. Hutchinson, and J. P. Larsen, “Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia,”
Int. J. Geriat. Psychiat.
, No. 10, 937–941 (2003).
C. Ballard, M. Piggott, and M. Johnson, “Delusions associated with elevated muscarinic binding in dementia with Lewy bodies,”
, No. 6, 868–876 (2000).
S. R. Beach and R. Schulz, “Caregiving as a risk factor for mortality: the Caregiver Health Effects Study,”
J. Amer. Med. Assoc.
, No. 23, 2215–2219 (1999).
N. I. Bohnen, D. I. Kaufer, L. S. Ivanco, et al., “Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study,”
: No. 12, 1745–1748 (2003).
N. I. Bohnen, D. I. Kaufer, R. Hendrickson, et al., “Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia,”
, No. 2, 242–247 (2005).
J. L. Boyd, C. A. Cruikshank, C. W. Kenn, et al., “Cognitive impairment and dementia in Parkinson's disease: a controlled study,”
, No. 3, 911–921 (1991).
R. Bullock and A. Cameron, “Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series,”
Curr. Med. Res. Opin.
, No. 5, 258–264 (2002).
M. J. Catalan-Alonso and J. Del Val, “Dopaminomimetic psychosis in Parkinson's disease: first symptom of early dementia?”
, No. 11, 1085–1087 (2001).
J. L. Cummings, M. Mega, K. Gray, et al., “The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia,”
, No. 12, 2308–2314 (1994).
C. Da Cunha, M. E. Angelucci, N. S. Canteras, et al., “The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities,”
Cell Mol. Neurobiol.
, No. 3, 227–237 (2002).
E. Duran Ferreras, J. Chacon, and J. A. Quintana, “The role of olanzapine in Parkinsonian dopaminergic psychosis,”
, No. 7, 691–696 (2002).
K. R. Edwards, L. Hershey, and L. Wray, “Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis,”
Dement. Geriat. Cogn. Disord.
, Supplement 1, 40–48 (2004).
R. L. Ernst and J. W. Hay, “The US economic and social costs of Alzheimer's disease revisited,”
Amer. J. Public Health
, No. 8, 1261–1264 (1994).
G. Fabbrini, P. Barbanti, C. Aurilia, et al., “Donepezil in the treatment of hallucinations and delusions in Parkinson's disease,”
, No. 1, 41–43 (2002).
G. Fenelon, F. Mahieux, R. Huon, et al., “Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors,”
, No. 7, 733–745 (2000).
J. M. Graham, R. A. Grunewald, and H. J. Sagar, “Hallucinosis,”
J. Neurol. Neurosurg. Psychiat., 63, No. 5, 434–440 (1967).
D. Grossi, L. Trojano, and M. T. Pellecchia, “Frontal dysfunction contributes to the genesis of hallucinations in non-demented Parkinsonian patients,”
Int. J. Geriat. Psychiat.
, No. 7, 668–673 (2005).
K. Ito, A. Nagano-Saito, T. Kato, et al., “Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[
F]fluoro-L-dopa PET study,”
, No. 6, 1358–1365 (2002).
I. Leroi, J. Brandt, and S. G. Reich, “Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease,”
Int. J. Geriat. Psychiat.
, No. 1, 1–8 (2004).
T. Mori, M. Ikeda, and R. Fukuhara, “Correlation of visual hallucinations with occipital rCBF changes by donepezil in DLB,”
, No. 6, 935–937 (2006).
K. Okada, N. Suyama, H. Oguro, et al., “Medication-induced hallucination and cerebral blood flow in Parkinson's disease,”
, No. 5, 365–368 (1999).
An Essay on the Shaking Palsy, Sherwood, Neely and Jones, London (1817), p. 66.
E. Perry, D. Irving, J. M. Kerwin, et al., “Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease,”
Alzheimer. Dis. Assoc. Disord.
, No. 2, 69–79 (1993).
I. H. Richard, A. W. Justus, N. H. Greig, et al., “Worsening of motor function and mood in a patient with Parkinson's disease after pharmacologic challenge with oral rivastigmine,”
, No. 6, 296–299 (2002).
M. Rosler, “The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia,”
Int. J. Clin. Pract., 127, Supplement 1, 20–36 (2002).
A. J. Saykin, H. A. Wishart, and L. A. Rabin, “Cholinergic enhancement of frontal lobe activity in mild cognitive impairment,”
, No. 7, 1574–1583 (2004).
W. S. Shaw, T. L. Patterson, and S. J. Semple, “Longitudinal analysis of multiple indicators of health decline among spousal caregivers,”
Ann. Behav. Med.
, No. 2, 101–109 (1997).
C. Summerfield, B. Gomez-Anson, E. Tolosa, et al., “Dementia in Parkinson's disease: a proton magnetic resonance spectroscopy study,”
, No. 9, 1415–1420 (2002).
T. Sunderland, J. L. Hill, A. M. Mellow, et al., “Clock drawing in Alzheimer's disease: a novel measure of dementia severity,”
J. Amer. Geriat. Soc.
, No. 5, 725–729 (1989).
P. N. Tariot, P. R. Solomon, J. C. Morris, et al., “A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group,”
Neurol., 54, No. 12, 2269–2276 (2000).
E. Y. Uc, M. Rizzo, and S. W. Anderson, “Visual dysfunction in Parkinson disease without dementia,”
, No. 12, 1907–1913 (2005).
C. H. Van Dyck, P. Tariot, M. Farlow, et al., “Memantine/donepezil dual-therapy is superior to placebo/donepezil for treatment of moderate to severe Alzheimer's disease,” in:
Abstracts of the 6th International Conference on Alzheimer's Disease and Parkinson's Disease, Seville, Spain (2003), p. 491.
R. J. Van Marum and P. A. Jansen, “Increased risk of stroke during the use of olanzapine or risperidone in patients with dementia,”
Ned. Tijdschr. Geneeskd.
, No. 4, 165–167 (2005).
S. P. Woods and A. I. Troster, “Prodromal fontal/executive dysfunction predicts incident dementia in Parkinson's disease,”
J. Int. Neuropsychol. Soc.
, No. 1, 17–24 (2003).
C. Zarow, S. A. Lyness, J. A. Mortimer, and H. C. Chaul, “Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer's and Parkinson's diseases,”
, No. 3, 337–341 (2003).
I. Zhang, F. Zhou, and J. A. Dani, “Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release,”
, No. 3, 538–544 (2004).
PubMed CrossRef Copyright information
© Springer Science+Business Media, Inc. 2008